Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

Overview of attention for article published in Cancer Discovery, February 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 97 X posts from 51 X users, with an upper bound of 394,604 followers.

RT @VivekSubbiah: 16 b. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer @CD_AA…

RT @VivekSubbiah: 16 b. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer @CD_AA…

RT @VivekSubbiah: 16 b. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer @CD_AA…

16 b. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer @CD_AACR @ElizSMcKenna https://t.co/X6BOjQR2Qi

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 93 additional X posts.